Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Gap Inc (GAP) Price & Performance

DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Gap Inc — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Gap Inc trades at $20.7 (market cap $7.74B). The key difference: DexCom, Inc. is far larger — about 4.3× Gap Inc's market cap, and Gap Inc pays a 3.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

DXCMGAP
Market Cap
$33.08B$7.74B
Sector
HealthConsumer Cyclical
52-Week High
$89.53$29.13
52-Week Low
$54.84$18.35
Enterprise Value
$32.53B$10.82B
Dividend Yield
3.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.

Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.

Gap Inc

Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.

The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.

Returns comparison

Trailing returns across standard periods

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Gap Inc

Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.

Read more on GAP